---
title: CDMO Daily News — September 27, 2026
slug: daily-news-2026-09-27-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: September 27 CDMO daily: Bramble Bio Signs 18-Month Manufacturing Agreement With VERIGRAFT for P-TEV Clinical Trial — Bramble Bio's Warsaw facility gains a…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-09-27-cdmo
published_at: 2026-09-27T00:00:19.478Z
last_updated: 2026-09-27T00:00:57.485Z
---

### [Bramble Bio](/companies/bramble-bio) Signs 18-Month Manufacturing Agreement With VERIGRAFT for P-TEV Clinical Trial
- [Bramble Bio](/companies/bramble-bio) (FamiCord AG's CDMO brand) will conduct technology transfer and GMP manufacturing of P-TEV, a tissue-engineered vein, at its Warsaw, Poland facility.
- The ~18-month collaboration supports VERIGRAFT's TECVI-2 Phase II/III trial launching Q1 2027 across Spain, Poland, and the Netherlands; contract value estimated in low single-digit millions of euros.

**Operational Impact**

[Bramble Bio](/companies/bramble-bio)'s Warsaw facility gains a high-complexity cell and tissue-engineering manufacturing contract supporting a pivotal Phase II/III trial, demonstrating capacity for personalized biological grafts and donor-tissue sourcing across three European markets.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/famicord-ag-signs-manufacturing-agreement-with-verigraft-for-p-tev)*

## References

1. [PharmaSource RSS — Bramble Bio Signs 18-Month Manufacturing Agreement With VERIGRAFT for P-TEV Clinical Trial](https://pharmasource.global/content/news/cdmo-news/famicord-ag-signs-manufacturing-agreement-with-verigraft-for-p-tev)

Source: https://www.cdmo.directory/posts/daily-news-2026-09-27-cdmo